A Phase II Study of Neo-adjuvant Erlotinib for Operable Stage IIB or IIIA Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Activation Mutations.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 27 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 17 Nov 2011 New trial record